| Literature DB >> 14739667 |
J Philip Kuebler1, Timothy Moore, James Pritchard, Eric Kraut.
Abstract
A phase II trial of CI-958 (NSC #635371), a new benzothiopyranoindazole was performed in patients with hormone refractory prostate carcinoma using prostate specific antigen (PSA) levels for response assessment. Twenty-two patients were entered on this study and twenty one were eligible. Toxicity consisted mainly of granulocytopenia (71% grade 3 or 4), but there were no significant infections. Two patients were removed from study due to asymptomatic decreases in cardiac ejection fraction. Of 21 evaluable patients, there were four responders (19%, CI 0-35%).Entities:
Mesh：
Substances：
Year: 2004 PMID： 14739667 DOI： 10.1023/B:DRUG.0000011795.82694.80
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850